Previous 10 | Next 10 |
Fulgent Genetics, Inc. (FLGT) Q1 2022 Earnings Conference Call May 3, 2022, 04:30 PM ET Company Participants Nicole Borsje - IR Ming Hsieh - CEO Brandon Perthuis - Chief Commercial Officer Larry Weiss - Chief Medical Officer Paul Kim - CFO Conference Call Participants Kevin DeGeeter - Oppenhe...
Fulgent Genetics (NASDAQ:FLGT) raised its 2022 revenue guidance to $660M (from $600M) but also lowered its full-year non-GAAP net income outlook to $6 per share (from $7). The genetic testing services company saw its net income in Q1 2022 decline 23% to ~154M ($4.93 per diluted share) compare...
The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Fulgent Genetics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Fulgent Genetics press release (NASDAQ:FLGT): Q1 Non-GAAP EPS of $5.08 beats by $1.22. Revenue of $320.27M beats by $19.77M. Outlook: Q2: Total Revenue of approximately $125 million; Core Revenue of approximately $40 million, representing growth of 78% year-over-year. Consensus EPS ...
Revenue totals $320.3 million Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million Raises full year revenue outlook to $660 million from previously announced $600 million Raises full year core revenue outlook to $180 million from previously...
New oncology laboratory will focus on pathology and molecular services, particularly next generation sequencing Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testi...
Fulgent Genetics (NASDAQ:FLGT) Q1 consensus EPS estimate is $3.86 (-41.4% Y/Y) and consensus revenue estimate is $300.5M (-16.4% Y/Y). FLGT is scheduled to announce Q1 earnings results tomorrow, May 3, after market close. Over the last 2 years, FLGT has beaten EPS estimates 75%...
ABNB, ACHC, ADC, AHT, AIG, AIZ, AKAM, ALR, AMCR, AMD, ANDE, APPH, AQST, ATEN, AYX, BFAM, BGFV, BLKB, BNFT, BNL, BTG, BXC, CGBD, CHCT, CNDT, CNR, COKE, CRK, CRUS, CTSO, CWH, CZR, DENN, DHC, DMTK, EGY, EHTH, EIX, ENLC, ENVA, EQX, EXR, FLGT, FPI, FRSH, GLAD, GLRE, GNW, GPOR, GRBK, HASI, HLF, HRZ...
Investing in a growth stock can be risky if the catalyst behind its strong numbers disappears. Over the past couple of years, COVID-19 has led to some strong results for certain companies while others have faltered as a result of the pandemic. A stock that did well due to the pandemic w...
AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC. PR Newswire NEW YORK , April 27, 2022 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announc...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...